Pharmaceutical Technology

JULY 12, 2022

Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of biotechnology company ViaCyte in a deal totalling $320m in cash. Topic sponsors are not involved in the creation of editorial content. Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

Manufacturing 110

Manufacturing Pharmaceutical Safety 110

Pharmaceutical Technology

DECEMBER 12, 2022

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. Kite will carry out the manufacturing following the technical transfer. Free Whitepaper.

Manufacturing 105

Manufacturing Marketing Pharmaceutical Patients 105

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Marketing 98

Marketing Pharmaceutical Manufacturing 98

Pharmaceutical Technology

APRIL 3, 2023

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. The company has been recently focusing on plasmid design and manufacturing through acquisitions of Xpress Biologics this year and e-Zyvec in 2022.

Media 98

Media Pharmaceutical Marketing Manufacturing 98

Pharmaceutical Technology

MAY 2, 2023

Marker Therapeutics has reached a non-dilutive agreement to sell cell manufacturing assets to CellReady for $19m in cash. CellReady is a newly created contract development and manufacturing organisation (CDMO) founded by Marker board member and co-founder John Wilson. Both firms expect to complete the deal on 26 June 2023.

Manufacturing 52

Manufacturing Leads Management Pharmaceutical 52

Pharmaceutical Technology

JULY 18, 2022

Quoin Pharmaceuticals and Endo International subsidiary Endo Ventures have signed a licence and distribution agreement and a supply agreement to develop, register, supply, market and distribute the former’s QRX003 exclusively in Canada. A lead product of Quoin, QRX003 is a topical lotion intended to treat Netherton Syndrome.

Distribution 64

Distribution Marketing Networking Manufacturing 64

Pharmaceutical Technology

AUGUST 26, 2022

ElevateBio has signed a long-term strategic collaboration with the University of Pittsburgh, US, to establish a biomanufacturing centre for expediting cell and gene therapy development. Topic sponsors are not involved in the creation of editorial content.

Manufacturing 64

Manufacturing Engineering Pharmaceutical 64

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. In 2021, Moderna had a net income of $12.2

Manufacturing 98

Manufacturing Government Sales Pharmaceutical 98

Spotio

APRIL 16, 2024

Each one will teach your reps to close more deals—often in less time and with less effort than before. Effective industrial sales training programs teach salespeople to close deals consistently in this competitive environment. This is much easier said than done, of course. And no, it’s not too good to be true.) The result?

Training 52

Training Sales Prospecting Sales Management 52

Pharmaceutical Technology

AUGUST 25, 2022

Sonoma Biotherapeutics has signed a lease agreement for setting up an 83,000ft² research and development (R&D) and manufacturing centre for cell therapies. A cGMP-compliant production facility will be housed at the centre for manufacturing cell products at scale.

Manufacturing 52

Manufacturing Engineering Pharmaceutical Patients 52

Pharmaceutical Technology

JUNE 9, 2023

Astellas Pharma (Astellas) has entered an exclusive licence deal with Kate Therapeutics (KateTx) to develop and commercialise KT430. KateTx will receive an undisclosed upfront payment from Astellas for an exclusive global licence to develop, manufacture and commercialise KT430.

Pharma 59

Pharma Medicine Manufacturing Patients 59

Pharmaceutical Technology

MARCH 27, 2023

Technology-focused biomanufacturing company National Resilience has signed a $410m long-term loan financing deal to establish a resilient end-to-end biomanufacturing capacity. The company expects to manufacture a billion vaccines doses in its manufacturing network in the US, using the long-term financing deal.

Manufacturing 52

Manufacturing Government Competition Networking 52

Pharmaceutical Technology

JUNE 12, 2023

Quell Therapeutics and AstraZeneca have entered a collaboration, exclusive option and licence deal for the development, manufacturing and commercialisation of engineered T-regulator (Treg) cell therapies for autoimmune diseases. Topic sponsors are not involved in the creation of editorial content.

Engineering 52

Engineering Manufacturing Leads Sales 52

Pharmaceutical Technology

DECEMBER 14, 2022

Merck and Synplogen have signed a non-binding Memorandum of Understanding (MoU) to expedite the development and manufacturing of viral vector-based gene therapy applications. The firms intend to merge their expertise to provide simplified viral vector gene therapy development, production and testing in Japan.

Manufacturing 52

Manufacturing Engineering Education Training 52

Pharmaceutical Technology

JUNE 2, 2023

Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material. The company is developing new and differentiated gene therapies for the treatment of serious, but common eye diseases.

Biopharma 52

Biopharma Manufacturing Leads Pharmaceutical 52

Pharmaceutical Technology

OCTOBER 26, 2022

SK bioscience has signed a new collaboration agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop messenger ribonucleic acid (mRNA) vaccines for infectious diseases. For developing the mRNA vaccine platform, SK bioscience will utilise the Japanese encephalitis virus (JEV) and Lassa virus.

Pharmaceutical 52

Pharmaceutical Manufacturing 52

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. According to the deal, Orna is eligible to receive an upfront payment of $150m from Merck.

Pharmaceutical 59

Pharmaceutical Manufacturing Medicine Sales 59

Pharmaceutical Technology

OCTOBER 13, 2022

Inceptor Bio has partnered with cell engineering technology company Avectas to improve CAR-T cell therapies’ development and manufacturing to treat solid tumours. Under the collaboration deal, Inceptor Bio will use the Solupore technology from Avectas instead of electroporation for engineering T cells to yield a healthier T cell.

Engineering 59

Engineering Pharmaceutical Manufacturing 59

Pharmaceutical Technology

AUGUST 11, 2022

GentiBio and Bristol Myers Squibb (BMS) have signed a multi-year partnership agreement for developing new engineered Treg therapies for inflammatory bowel disease (IBD) patients. These therapies will be developed for re-instating immune tolerance and repairing tissue in IBD.

Engineering 52

Engineering Pharmaceutical Manufacturing Patients 52

Pharmaceutical Technology

MARCH 1, 2023

Tevard Biosciences and Vertex Pharmaceuticals have announced a four-year global research partnership to develop new tRNA-based therapies to treat Duchenne muscular dystrophy (DMD) patients. The deal offers access to the platforms of Tevard to discover and develop tRNA-based therapies.

Manufacturing 52

Manufacturing Pharmaceutical Patients Leads 52

Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. Topic sponsors are not involved in the creation of editorial content.

Manufacturing 52

Manufacturing Patients Leads Pharmaceutical 52

Pharmaceutical Technology

JANUARY 12, 2023

Solid Biosciences has entered a strategic research collaboration with Phlox Therapeutics to expedite the development of new therapies for rare cardiac diseases. Under the research partnership deal, the companies will develop new precision genetic medicines for a severe form of genetic dilated cardiomyopathy (DCM).

Manufacturing 52

Manufacturing Pharmaceutical Patients Medicine 52

Pharmaceutical Technology

MAY 5, 2023

Switzerland-based Siegfried has purchased a 95% stake in DiNAMIQS, a biotechnology firm that focuses on the development and production of viral vectors for cell and gene therapies. Siegfried will leverage DiNAMIQS’ capabilities to commercial scale by constructing a facility that complies with good manufacturing practice standards.

Leads 52

Leads Manufacturing Management Pharmaceutical 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Under the deal, both companies will partner on the research and preclinical studies, which will be funded by Moderna.

Engineering 59

Engineering Pharmaceutical Manufacturing Medicine 59

Cesare Ferrari

JUNE 17, 2022

For a medical device manufacturer, finding a valuable partner could be a challenge; it requires a rigorous process and a bit of luck. Well, that’s the topic of this post. For example, A distributors, which are the strongest customers for the manufacturer, should always get the best support within the bounds of company policies.

Medical 52

Medical Sales Management Manufacturing Sales 52

Pharmaceutical Technology

JANUARY 4, 2023

Under the deal, Catamaran will get non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and the ExPERT platform, for which the latter will receive platform licensing fees and programme-related revenue. Topic sponsors are not involved in the creation of editorial content.

Engineering 52

Engineering Pharmaceutical Manufacturing Medicine 52

Celeritas

MARCH 3, 2023

Getting quick, detailed, and accurate reports on animal health related topics a game-changer. Animal health is a sector that utilizes the most complex processes and is intensely data-rich. Rather we will be delving into the use of data analytics in each sub-field. The rest won’t be as extensive, we promise.

Food 98

Food Training Prescription Management 98

PM360

DECEMBER 20, 2023

Araris Biotech , a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich that is developing proprietary antibody-drug conjugate (ADC)-linker technology, got funding through a grant. The deal is expected to close in 2024. This method is often quicker than a public offering and has less strict regulations.

Management 109

Management Marketing Healthcare Healthcare 109

Medico Reach

JULY 3, 2022

Developing a new medical device entails a long process that begins with an idea and ends with a completed product. It would help if you began considering prudent strategies for developing a comprehensive medical device product launch. However, the success or failure of the product heavily depends on its debut. Create a Marketing Plan.

Medical 97

Medical Food and Drug Administration Training Marketing 97

Spotio

AUGUST 31, 2023

You just need to develop and implement a solid solar sales strategy. The most reliable way to close deals in this industry is to remind potential customers of the money your system will save them. But if you’re in solar sales, you know that it’s not all sunshine and rainbows. How can you succeed in this kind of environment?

Prospecting 52

Prospecting Sales Engineering Leads 52

pharmaphorum

DECEMBER 8, 2022

The LSC is a forum for government-to-industry discussion and it last met on the 28 November 2022 with special guest, Prime Minister Rishi Sunak. That’s all you can find out. Ironically, it’s also got the ubiquitous ‘Is this page useful?’ I’ve answered that with a resounding ‘no’ a long time ago, but no action was taken). Life sciences lobbying.

Government 90

Government Medicine Pharmaceutical Patients 90

Map My Customers

AUGUST 2, 2022

Whether for healthcare device or equipment manufacturers or pharmaceutical companies, medical sales reps sell the company’s products to healthcare professionals. The reps serve as the trusted liaison between the manufacturer and the customers. This is base salary plus commission.) What Does a Medical Sales Rep Do?

Medical sales reps 79

Medical sales reps Medical sales Sales Medical 79

The Brooks Group

FEBRUARY 13, 2020

However, when working with those who sell into agriculture, we may deliver training that deals more with selling through the distributor channel. However, when working with those who sell into agriculture, we may deliver training that deals more with selling through the distributor channel. Make distractions an ally.

Training 52

Training Sales Sales Management Medical sales 52

PM360

SEPTEMBER 15, 2022

To work directly with patients to develop medications, service offerings, information toolkits, and anything else that could address their unmet needs. The increased relevance and usage of social media is significant and is likely to be integral in gathering insights to inform the drug development pathway. Cure,” he said.

Patients 98

Patients Healthcare Healthcare Marketing 98

Evolve Your Success

DECEMBER 19, 2023

Fred shares his diverse experiences, from influencing change within organizations to the significance of mentorship in career development. Career success in MedTech is not just about climbing the corporate ladder; it’s about relentlessly advocating for patients, embracing change, and, above all, never giving up. Tune in now!

Engineering 52

Engineering Patients Medical Sales 52

Pharmaceutical Technology

FEBRUARY 24, 2023

AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics for the development of targeted genetic medicines to treat eye diseases with high unmet needs. Under the expanded deal terms, Capsida will take charge of capsid discovery efforts for all the programmes, along with process development and early clinical manufacturing.

Engineering 52

Engineering Manufacturing Medicine Leads 52

European Pharmaceutical Review

FEBRUARY 23, 2023

Given the widely reported challenges of validation and qualification of microbiological methods, as well as lab compliance and keeping up with compendial amendments, I have steered away from these topics here. I would add that these do not necessarily represent the opinions of those organisations I support or work for.

Pharmaceutical 100

Pharmaceutical Management Manufacturing Recruitment 100